Hematology

Latest News

Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

May 17th 2025

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

May 16th 2025

Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com
Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

May 16th 2025

Other AF prediction models have been proposed, including one with a machine-learning approach, but earlier models may not apply to patients taking second-generation BTKis. | Image Credit: sovova - stock.adobe.com
Novel AI-Based Score Could Pinpoint AF Risk in Patients With CLL on BTKis

May 15th 2025

One of the key ways to manage thromboembolic event risk in PV is by controlling hematocrit, often by prescribing hydroxyurea. If patients develop resistance to the therapy, however, they face a higher risk of mortality. | Image credit: keetazalay - stock.adobe.com
Machine Learning Model Identifies Hydroxyurea Resistance Markers in PV

May 6th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

BCMA-Targeted CAR T-Cell Therapy Effective in MM, but With Caveats, Analysis Finds
December 16th 2020

BCMA-Targeted CAR T-Cell Therapy Effective in MM, but With Caveats, Analysis Finds

Jared Kaltwasser
A new meta-analysis finds high rates of efficacy and high rates of toxicity in multiple myeloma patients treated with B-cell maturation agent (BCMA)-targeted chimeric antigen receptor (CAR)- T cells.
Tumor Lysis Syndrome Risk May Rise With Use of Bortezomib for MM in Men
December 11th 2020

Tumor Lysis Syndrome Risk May Rise With Use of Bortezomib for MM in Men

Jared Kaltwasser
The research raises the possibility that the type of therapy used can increase the risk of tumor lysis syndrome from low to moderate in men with multiple myeloma (MM).
Exploring Biomarker-Based Risk Stratification in Smoldering Multiple Myeloma
December 9th 2020

Exploring Biomarker-Based Risk Stratification in Smoldering Multiple Myeloma

Jared Kaltwasser
The science around risk stratification in patients with smoldering multiple myeloma (SMM) has been evolving over the past 2 decades. A new study validates some, though not all, of the proposed biomarkers.
Study Examines Trends in Mortality Rates of Multiple Myeloma in US Adults
December 4th 2020

Study Examines Trends in Mortality Rates of Multiple Myeloma in US Adults

AJMC Staff
The United States is becoming older, more diverse, and more overweight, and these changes may influence future trends in certain hematological cancers.
Considerations for Designing ePRO Interventions for Patients With RRMM
December 4th 2020

Considerations for Designing ePRO Interventions for Patients With RRMM

Skylar Jeremias
Patients and health care providers evaluated the use of an electronic patient-reported outcome (ePRO) intervention for use in a clinic setting for patients with relapsed or refractory multiple myeloma (RRMM).
Review Examines New Options for Patients With Aplastic Anemia
November 28th 2020

Review Examines New Options for Patients With Aplastic Anemia

AJMC Staff
Severe aplastic anemia used to have few options and mortality was high, but a new class of drugs offers some hope.
Real-World Data Confirm KRd Safety, Efficacy in RRMM
November 26th 2020

Real-World Data Confirm KRd Safety, Efficacy in RRMM

Jared Kaltwasser
New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma.
Selinexor Shows Promise in Combination With Daratumumab, Dexamethasone in RRMM
November 20th 2020

Selinexor Shows Promise in Combination With Daratumumab, Dexamethasone in RRMM

Jared Kaltwasser
The oral selective inhibitor of nuclear export could provide a new therapeutic avenue in daratumumab-naive patients with relapsing refractory multiple myeloma (RRMM).
Hypercalcemia in Multiple Myeloma Leads to Poor Prognosis
November 18th 2020

Hypercalcemia in Multiple Myeloma Leads to Poor Prognosis

Jared Kaltwasser
New research attempts to answer some of the mystery related to the causes and impact of hypercalcemia in patients with newly diagnosed multiple myeloma.
Enhanced CAR T cell
November 12th 2020

Radiation Does Not Disrupt CAR T-Cell Therapy in Patients With MM, Study Finds

Jared Kaltwasser
New research suggests it’s not disruptive to give radiation therapy to patients who are awaiting CAR T-cell therapy for relapsed or refractory multiple myeloma.
Multiple myeloma iPad display
November 10th 2020

Once-Weekly KRd Shows Promise in Newly Diagnosed MM

Jared Kaltwasser
Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally successful.
Circulating Cell-Free DNA Could Be Marker of Progression in Multiple Myeloma
November 6th 2020

Circulating Cell-Free DNA Could Be Marker of Progression in Multiple Myeloma

Jared Kaltwasser
A new study suggests a potential new marker that could be used to track response to therapy and disease progression in patients with multiple myeloma.
Carfilzomib molecule
November 3rd 2020

New Analysis Aims to Characterize Patients With Best Carfilzomib Responses

Jared Kaltwasser
There did not appear to be any particular patient characteristics linked with best responses to carfilzomib in patients with multiple myeloma, with the exception of low serum lactate dehydrogenase.
Multiple myeloma
October 29th 2020

Use of Triplet Therapy Rose in R/R MM as Deaths Declined, Study Finds

Jared Kaltwasser
Newer therapies have led to a boost in the number of patients with relapsed or refractory multiple myeloma (R/R MM) who are prescribed triplet regimens. As that shift has occurred, death rates appear to have dropped.
Older Patient
October 22nd 2020

Patients With MM Living Longer, but Elderly Still Face Worse Survival

Jared Kaltwasser
New data show that despite major improvements in survival rates in patients with multiple myeloma (MM), older patients with the malignancy have benefited less than younger patients.
Drops in Circulating MicroRNA-451a Could Be Sign of MM Relapse
October 21st 2020

Drops in Circulating MicroRNA-451a Could Be Sign of MM Relapse

Jared Kaltwasser
Investigators may have found a minimally invasive way to predict which patients with multiple myeloma are about to experience a relapse.
Drug cost concept
October 13th 2020

CML Treatment Costs Continue to Rise Despite Availability of Generic Imatinib

Jared Kaltwasser
Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib.
Intestines
October 13th 2020

Colon Perforations in MM, While Rare, Linked With Corticosteroids

Jared Kaltwasser
A new report confirms earlier research that colon perforation in multiple myeloma is associated with corticosteroids, though the exact cause of the apparent link is not known.
Picture of bacteria
October 7th 2020

MM Staging, Severe Anemia Linked With High Infection and Mortality Risk

Jared Kaltwasser
Newly diagnosed patients with multiple myeloma (MM) face a high risk of infection. A new study helps elucidate key risk factors.
MRD Potential in MM Undeniable, Even if Not Ready for Use Yet, Review Says
September 30th 2020

MRD Potential in MM Undeniable, Even if Not Ready for Use Yet, Review Says

Jared Kaltwasser
A new review article said there are hurdles to bringing minimal residual disease (MRD) into the clinic as a decision-making tool, but the day is likely not far away.
Frailty Definitions Too Imprecise in Patients With MM, New Paper Suggests
September 27th 2020

Frailty Definitions Too Imprecise in Patients With MM, New Paper Suggests

Jared Kaltwasser
A subset of patients with multiple myeloma (MM) are not eligible for the most effective therapies, but a new study suggests clinicians may be inaccurately defining that subset.
Medical question image
September 23rd 2020

Review Updates Mechanisms Underlying Proteasome Inhibitor Resistance in MM

Jared Kaltwasser
Proteasome inhibitors have brought major advances in the treatment of multiple myeloma (MM), but eventual drug resistance remains a serious hurdle.
FDA Accepts Anti-BCMA Ide-cel for MM for Priority Review
September 22nd 2020

FDA Accepts Anti-BCMA Ide-cel for MM for Priority Review

Allison Inserro
FDA will review the first chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of multiple myeloma (MM) in adults who have not responded or have relapsed after at least 3 other therapies.
Treatment, Access to Caregivers Among Factors Affecting QOL in MM
September 18th 2020

Treatment, Access to Caregivers Among Factors Affecting QOL in MM

Jared Kaltwasser
A study of patients with multiple myeloma in China found many do not have access to a caregiver and most have to travel to another city to receive treatment.
Dollar sign
September 15th 2020

End-Organ Damage Leads to Spike in Economic Costs of Sickle Cell Disease

Jared Kaltwasser
Sickle cell disease is a costly disease for patients, but when those patients suffer from end-organ damage, the costs jump significantly.
Study Finds Limits to sCR Compared With MRD in Tracking MM Response
September 11th 2020

Study Finds Limits to sCR Compared With MRD in Tracking MM Response

Jared Kaltwasser
A new study suggests stringent complete response is less meaningful than minimal residual disease status when evaluating patients with multiple myeloma.
Education Level Linked to Outcomes in Patients With MM
September 9th 2020

Education Level Linked to Outcomes in Patients With MM

Jared Kaltwasser
New data suggests a patient’s education level can be an important factor in the disease outcomes of patients with multiple myeloma.
Red blood cells
September 3rd 2020

Combination Therapy Benefits High-Risk Patients With MM, Study Says

Jared Kaltwasser
A new analysis found patients with high-cytogenetic-risk multiple myeloma benefitted from adding daratumumab to their therapy.
plasma cells
August 31st 2020

Plasma Exchange Therapy MM Use, Cost Rose During Past 25 Years

Jared Kaltwasser
A new analysis finds therapeutic plasma exchange has become more costly, and more common among patients with multiple myeloma.
Picture of red blood cells
August 26th 2020

MRD an Exciting Advance, but Not Ready for MM Care Yet, Review Says

Jared Kaltwasser
A new opinion article suggests minimal residual disease (MRD) is not yet ready for “prime time” in the clinic, even though it’s already making a major impact on clinical trials.
<1
...
456789101112
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo